Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprot...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-05-01
|
Series: | Behavioral Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-328X/8/5/51 |
id |
doaj-e9b47749e1ea4969919e98a761c15a64 |
---|---|
record_format |
Article |
spelling |
doaj-e9b47749e1ea4969919e98a761c15a642020-11-25T01:57:41ZengMDPI AGBehavioral Sciences2076-328X2018-05-01855110.3390/bs8050051bs8050051Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s DiseaseIvonne Pedroso0Marité Garcia1Enrique Casabona2Lilia Morales3Maria Luisa Bringas4Leslie Pérez5Teresita Rodríguez6Ileana Sosa7Yordanka Ricardo8Arnoldo Padrón9Daniel Amaro10International Center for Neurological Restoration, La Habana 11300, CubaInternational Center for Neurological Restoration, La Habana 11300, CubaInternational Center for Neurological Restoration, La Habana 11300, CubaInternational Center for Neurological Restoration, La Habana 11300, CubaThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 610054, ChinaCenter of Molecular Immunology, La Habana 11300, CubaCenter of Molecular Immunology, La Habana 11300, CubaNational Center for the Production of Laboratory Animal Breeding, La Habana 10800, CubaInternational Center for Neurological Restoration, La Habana 11300, CubaInternational Center for Neurological Restoration, La Habana 11300, CubaCenter of Molecular Immunology, La Habana 11300, CubaIntroduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson’s disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition.http://www.mdpi.com/2076-328X/8/5/51cognitive 1neuroprotection 2Parkinson 3 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ivonne Pedroso Marité Garcia Enrique Casabona Lilia Morales Maria Luisa Bringas Leslie Pérez Teresita Rodríguez Ileana Sosa Yordanka Ricardo Arnoldo Padrón Daniel Amaro |
spellingShingle |
Ivonne Pedroso Marité Garcia Enrique Casabona Lilia Morales Maria Luisa Bringas Leslie Pérez Teresita Rodríguez Ileana Sosa Yordanka Ricardo Arnoldo Padrón Daniel Amaro Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease Behavioral Sciences cognitive 1 neuroprotection 2 Parkinson 3 |
author_facet |
Ivonne Pedroso Marité Garcia Enrique Casabona Lilia Morales Maria Luisa Bringas Leslie Pérez Teresita Rodríguez Ileana Sosa Yordanka Ricardo Arnoldo Padrón Daniel Amaro |
author_sort |
Ivonne Pedroso |
title |
Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_short |
Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_full |
Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_fullStr |
Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_full_unstemmed |
Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease |
title_sort |
protective activity of erythropoyetine in the cognition of patients with parkinson’s disease |
publisher |
MDPI AG |
series |
Behavioral Sciences |
issn |
2076-328X |
publishDate |
2018-05-01 |
description |
Introduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson’s disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition. |
topic |
cognitive 1 neuroprotection 2 Parkinson 3 |
url |
http://www.mdpi.com/2076-328X/8/5/51 |
work_keys_str_mv |
AT ivonnepedroso protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT maritegarcia protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT enriquecasabona protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT liliamorales protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT marialuisabringas protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT leslieperez protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT teresitarodriguez protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT ileanasosa protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT yordankaricardo protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT arnoldopadron protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease AT danielamaro protectiveactivityoferythropoyetineinthecognitionofpatientswithparkinsonsdisease |
_version_ |
1724973148541026304 |